Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- eflapegrastim
- Hycamtin (topotecan)
Interactions between your drugs
topotecan eflapegrastim
Applies to: Hycamtin (topotecan), eflapegrastim
Although eflapegrastim is prescribed to help boost the levels of white blood cells in patients undergoing chemotherapy, using it during or too soon after completion of a cycle of topotecan can sometimes have negative effects by prolonging the period during which your white blood cell counts remain low. This can make you more vulnerable to infections. In general, eflapegrastim works best when given at least 24 hours after finishing a course of topotecan. Talk to your doctor or pharmacist if you have any questions or concerns. Contact your doctor if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. There is also some evidence that use of eflapegrastim may increase the risk of a serious lung disorder that can occasionally develop during treatment with topotecan. You should seek immediate medical attention if you experience cough, fever, difficulty breathing, wheezing, and/or pale or bluish skin discoloration. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Zarxio
Zarxio (filgrastim-sndz) is biosimilar product used to treat neutropenia associated with ...
Neulasta
Neulasta is used to stimulate neutrophil growth and reduce infection risk (manifested by febrile ...
Mounjaro
Mounjaro is used for type 2 diabetes to help lower blood sugar levels. Mounjaro has also been shown ...
Neupogen
Neupogen (filgrastim) is used to treat neutropenia, a lack of certain white blood cells caused by ...
Fulphila
Fulphila is used for febrile neutropenia, neutropenia associated with chemotherapy
Nivestym
Nivestym is used for bone marrow transplantation, neutropenia, neutropenia associated with ...
Udenyca
Udenyca is used for febrile neutropenia, hematopoietic syndrome of acute radiation syndrome ...
Releuko
Releuko is used for bone marrow transplantation, neutropenia, neutropenia associated with chemotherapy
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.